The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism.
Abstract
Angiotensin II, when given in low doses, raises blood pressure slowly. When tested in vitro on vascular smooth muscle cells, it has mitogenic and trophic effects; it is not known if it has these effects in vivo. Our purpose was to determine whether vascular hypertrophy develops during slow pressor infusion of angiotensin II and, if so, whether it is pressure induced. Three experiments were done in rats infused subcutaneously with angiotensin II (200 ng/kg/min) by minipump for 10-12 days. Experiment 1: Angiotensin II gradually raised systolic blood pressure (measured in the tail) from 143 +/- 2 to 208 +/- 8 mm Hg (mean +/- SEM), significantly suppressing plasma renin and increasing threefold (NS) plasma angiotensin II. There was no loss of peptide in the pump infusate when tested at the end of the experiment. Experiment 2: In the perfused mesenteric circulation, vasoconstrictor responses to norepinephrine, vasopressin, and KCl were enhanced in rats given a slow pressor infusion of angiotensin II, but sensitivity of responses was not altered. This combination of changes suggests that vascular hypertrophy develops during slow pressor infusion of angiotensin II. Experiment 3: Vessel myography was done after angiotensin II infusion with and without a pressor response. Angiotensin II raised systolic blood pressure, increased heart weight, and produced myographic changes of vascular hypertrophy in the mesenteric circulation, increasing media width, media cross-sectional area, and media/lumen ratio. Hydralazine given with angiotensin II prevented the rise of pressure and the cardiac effect but not the vascular changes. Two-way analysis of variance showed that angiotensin II significantly increased media width, media cross-sectional area, and media/lumen ratio, all independent of hydralazine. Thus, although hydralazine inhibits the pressor and cardiac effects of angiotensin II, suggesting a pressor mechanism for the cardiac change, it does not inhibit structural vascular change, which suggests that at least part of the effect has a non-pressor mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mulvany, M. J., & Halpern, W. (1977) · Circulation Research · doi:10.1161/01.res.41.1.19 · Cited by 2,140
Self-citationAngiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.
Geisterfer, A. A., Peach, M. J., & Owens, G. K. (1988) · Circulation Research · doi:10.1161/01.res.62.4.749 · Cited by 1,065
McGregor, D. D. (1965) · The Journal of Physiology · doi:10.1113/jphysiol.1965.sp007572 · Cited by 639
Naftilan, A. J., Pratt, R. E., & Dzau, V. J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114032 · Cited by 623
Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells.
Berk, B. C., Vekshtein, V, Gordon, H. M., & Tsuda, T. (1989) · Hypertension · doi:10.1161/01.hyp.13.4.305 · Cited by 556
Mulvany, M. J., Hansen, O. K., & Aalkjaer, C. (1978) · Circulation Research · doi:10.1161/01.res.43.6.854 · Cited by 460
Self-citationPhenotype-dependent response of cultured aortic smooth muscle to serum mitogens.
Chamley-Campbell, J. H., Campbell, G. R., & Ross, R. (1981) · The Journal of cell biology · doi:10.1083/jcb.89.2.379 · Cited by 444
Neovascularization produced by angiotensin II.
Fernandez, L. A., Twickler, J., & Mead, A. (1985) · PubMed · Cited by 406
Folkow, B. (1978) · Clinical Science · doi:10.1042/cs055003s · Cited by 403 · cited 1×
“Increased thickness of the smooth muscle layer of resistance vessels, which is common in hypertension, may be a consequence and a contributory cause of increased arterial pressure.(1)-(2) According to Folkow(1) and Korner and his colleagues(3), the two processes interact as a vascular amplifier raising arterial pressu…”
BackgroundHarrap, S. B., van der Merwe, W. M., Griffin, S. A., MacPherson, F., & Lever, A. F. (1990) · Hypertension · doi:10.1161/01.hyp.16.6.603 · Cited by 339
Self-citation
Cited by
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Small artery structure in hypertension. Dual processes of remodeling and growth.
Heagerty, A. M., Aalkjaer, C., Bund, S. J., Korsgaard, N., & Mulvany, M. J. (1993) · Hypertension · doi:10.1161/01.hyp.21.4.391 · Cited by 645
Self-citationAngiotensin Receptors and Their Antagonists
Goodfriend, T. L., Elliott, M. E., & Catt, K. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606203342507 · Cited by 558
Xiao, L., & Harrison, D. G. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.01.013 · Cited by 545
Renal injury from angiotensin II-mediated hypertension.
Johnson, R. J., Alpers, C. E., Yoshimura, A., Lombardi, D., Pritzl, P., Floege, J., & Schwartz, S. M. (1992) · Hypertension · doi:10.1161/01.hyp.19.5.464 · Cited by 536
Higashi, M., Shimokawa, H., Hattori, T., Hiroki, J., Mukai, Y., Morikawa, K., Ichiki, T., Takahashi, S., & Takeshita, A. (2003) · Circulation Research · doi:10.1161/01.res.0000096650.91688.28 · Cited by 418
Spironolactone Improves Angiotensin-Induced Vascular Changes and Oxidative Stress
Virdis, A., Neves, M. F., Amiri, F., Viel, E., Touyz, R. M., & Schiffrin, E. L. (2002) · Hypertension · doi:10.1161/01.hyp.0000034738.79310.06 · Cited by 399
Vascular Smooth Muscle Growth: Autocrine Growth Mechanisms
Berk, B. C. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.999 · Cited by 383
De Ciuceis, C., Amiri, F., Brassard, P., Endemann, D. H., Touyz, R. M., & Schiffrin, E. L. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000181743.28028.57 · Cited by 350
Diep, Q. N., El Mabrouk, M., Cohn, J. S., Endemann, D., Amiri, F., Virdis, A., Neves, M. F., & Schiffrin, E. L. (2002) · Circulation · doi:10.1161/01.cir.0000016049.86468.23 · Cited by 345
SCHIFFRIN, E. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.05.023 · Cited by 327
Moreau, P., d’Uscio, L. V., Shaw, S., Takase, H., Barton, M., & Lüscher, T. F. (1997) · Circulation · doi:10.1161/01.cir.96.5.1593 · Cited by 324
Decreased blood pressure in NOX1‐deficient mice
Gavazzi, G., Banfi, B., Deffert, C., Fiette, L., Schappi, M., Herrmann, F., & Krause, K.-H. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.049 · Cited by 321
Remodeling and reparation of the cardiovascular system
Weber, K. T., Anversa, P., Armstrong, P. W., Brilla, C. G., Burnett, J. C., Cruickshank, J. M., Devereux, R. B., Giles, T. D., Korsgaard, N., Leier, C. V., et al. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90130-f · Cited by 312
Self-citationKarnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Brain Angiotensin II: New Developments, Unanswered Questions and Therapeutic Opportunities
Saavedra, J. M. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-005-4011-5 · Cited by 281
Sriramula, S., Haque, M., Majid, D. S. A., & Francis, J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.102152 · Cited by 278
Benetos, A., Gautier, S., Ricard, S., Topouchian, J., Asmar, R., Poirier, O., Larosa, E., Guize, L., Safar, M., Soubrier, F., et al. (1996) · Circulation · doi:10.1161/01.cir.94.4.698 · Cited by 271
Mechanisms of diabetic vasculopathy: an overview
Cooper, M. (2001) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)01323-6 · Cited by 267
Schiffrin, E. L., Deng, L. Y., & Larochelle, P. (1994) · Hypertension · doi:10.1161/01.hyp.23.1.83 · Cited by 264
Brink, M., Wellen, J., & Delafontaine, P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118698 · Cited by 262
Villa, E., Rabano, A., Albarran, O. G., Ruilope, L. M., & Garcia-Robles, R. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(98)00053-3 · Cited by 11
Inhibiting the Effects of Angiotensin on Cardiovascular Hypertrophy
Metsärinne, K. P., Stoll, M., Falkenhahn, M., Gohlke, P., & Unger, T. (1994) · Angiotensin Receptors · doi:10.1007/978-1-4615-2464-9_13 · Cited by 6
Metadata
- Authors
- Griffin, S. A., Brown, W. C., MacPherson, F., McGrath, J. C., Wilson, V. G., Korsgaard, N., Mulvany, M. J., & Lever, A. F.
- Venue
- Hypertension
- Published
- 1991-05
- Volume
- 17
- Issue
- 5
- Pages
- 626-635
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2142961055
- Cited by
- 391
- References
- 40
- FWCI
- 14.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.